Cetera Investment Advisers
STLN

Cetera Investment Advisers’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Cetera Investment Advisers’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$394K Buy
128,195
+103,908
+428% +$319K ﹤0.01% 3734
2025
Q4 		$86.5K Sell
24,287
-20,958
-46% -$77.7K ﹤0.01% 4437
2025
Q3 		$158K Buy
45,245
+27,700
+158% +$94.9K ﹤0.01% 4220
2025
Q2 		$36K Buy
17,545
+4,545
+35% +$11.4K ﹤0.01% 3994
2025
Q1 		$14.8K Buy
+13,000
New +$10.1K ﹤0.01% 3928

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Investment Advisers's STLN Position: Q1 2026 in Review

Cetera Investment Advisers increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 428% in Q1 2026, buying an estimated $319K and bringing the position to 128,195 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

Cetera Investment Advisers first reported a position in STLN in Q1 2025 and has held it in 5 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Cetera Investment Advisers held 128,195 shares of Starling Oncology Institute, Inc. Common Stock worth $394K as of Q1 2026.
  • Cetera Investment Advisers bought 103,908 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $319K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3734 holding.
  • Cetera Investment Advisers first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2025 and has held it in 5 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.